bluebird bio Inc (NASDAQ:BLUE) insider Jeffrey T. Walsh sold 1,500 shares of bluebird bio stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $150.16, for a total value of $225,240.00. Following the transaction, the insider now directly owns 36,995 shares in the company, valued at approximately $5,555,169.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Shares of NASDAQ BLUE traded down $5.45 during trading hours on Wednesday, hitting $147.55. The stock had a trading volume of 560,000 shares, compared to its average volume of 798,902. The stock has a market cap of $8.21 billion, a price-to-earnings ratio of -19.20 and a beta of 1.86. bluebird bio Inc has a 52 week low of $119.90 and a 52 week high of $236.17.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($2.91) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.30) by ($0.61). The firm had revenue of $7.80 million during the quarter, compared to the consensus estimate of $10.68 million. bluebird bio had a negative net margin of 1,281.01% and a negative return on equity of 31.57%. The company’s quarterly revenue was down 53.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.73) EPS. analysts predict that bluebird bio Inc will post -10.8 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Commonwealth Equity Services LLC lifted its holdings in bluebird bio by 24.7% in the 1st quarter. Commonwealth Equity Services LLC now owns 1,936 shares of the biotechnology company’s stock worth $330,000 after purchasing an additional 383 shares during the last quarter. CIBC Asset Management Inc lifted its holdings in bluebird bio by 28.5% in the 2nd quarter. CIBC Asset Management Inc now owns 1,780 shares of the biotechnology company’s stock worth $279,000 after purchasing an additional 395 shares during the last quarter. Winfield Associates Inc. lifted its holdings in bluebird bio by 12.4% in the 1st quarter. Winfield Associates Inc. now owns 3,620 shares of the biotechnology company’s stock worth $618,000 after purchasing an additional 400 shares during the last quarter. Dynamic Technology Lab Private Ltd lifted its holdings in bluebird bio by 43.2% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 2,040 shares of the biotechnology company’s stock worth $320,000 after purchasing an additional 615 shares during the last quarter. Finally, Usca Ria LLC lifted its holdings in bluebird bio by 10.3% in the 1st quarter. Usca Ria LLC now owns 6,720 shares of the biotechnology company’s stock worth $1,147,000 after purchasing an additional 630 shares during the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.
Several research firms have weighed in on BLUE. Cowen reaffirmed a “buy” rating on shares of bluebird bio in a research note on Monday, August 6th. Cantor Fitzgerald set a $122.00 target price on bluebird bio and gave the company a “sell” rating in a research note on Wednesday, September 5th. BMO Capital Markets reaffirmed a “buy” rating and set a $208.00 target price on shares of bluebird bio in a research note on Friday, August 3rd. Piper Jaffray Companies reaffirmed a “buy” rating on shares of bluebird bio in a research note on Thursday, August 2nd. Finally, Maxim Group lowered their target price on bluebird bio to $163.00 and set a “hold” rating on the stock in a research note on Monday, July 30th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $212.05.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Recommended Story: How Do You Make Money With Penny Stocks?
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.